Home > Healthcare > Medical Devices > Therapeutic Devices > Outpatient Oncology Infusion Market

Outpatient Oncology Infusion Market Trends

Report ID: GMI5268
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Outpatient Oncology Infusion Market Trends

The market is experiencing several key trends driving its growth and evolution. These include the increasing geriatric population and a shift in patient preferences towards outpatient facilities due to enhanced comfort, cost efficiency, and technological advancements. Additionally, changes in healthcare policies, along with improved survival rates, are expected to have a positive impact on the market during the forecast period.

Governments worldwide have been actively working to raise awareness about cancer treatment, aiming to reduce the disease burden and support the growth of the oncology outpatient infusion market. For example, in February 2022, the U.S. government relaunched the Cancer Moonshot program, with a mission to accelerate progress in cancer research and treatment. The program sets ambitious goals, such as reducing cancer death rates by at least 50% over the next 25 years. Such initiatives, which focus on increasing disease awareness, are expected to drive market growth.
Government programs are instrumental in driving the market's expansion by implementing policies and initiatives that improve accessibility, affordability, and the quality of care.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The outpatient oncology infusion industry was valued at USD 2.4 billion in 2023 and is anticipated to register a 10.6% CAGR from 2024 to 2032, driven by technological advancements in infusion pumps, the increasing prevalence of cancer, and the expansion of healthcare policies and insurance coverage.

The infusion pumps segment of outpatient oncology infusion market generated a revenue of USD 1.2 billion in 2023, due to their precision in drug delivery, ability to administer complex chemotherapy regimens, and improved patient outcomes.

North America outpatient oncology infusion industry was worth USD 1 billion in 2023 and will showcase a 10% CAGR through 2032, stimulated by the rising prevalence of cancer.

Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, and Moog, Inc., among others.